Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 48: 653-655, 2002;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Meier, C.
Right arrow Articles by Summers, A. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Meier, C.
Right arrow Articles by Summers, A. M.
Related Collections
Right arrow Molecular Diagnostics and Genetics
(Clinical Chemistry. 2002;48:653-655.)
© 2002 American Association for Clinical Chemistry, Inc.

Technical Briefs

Accuracy of Expected Risk of Down Syndrome Using the Second-Trimester Triple Test

Chris Meier1, Tianhua Huang1a, Philip R. Wyatt1 and Anne M. Summers1

1 Genetics, North York General Hospital, Toronto, M2K 1E1 Canada

aGenetics, North York General Hospital, 4001 Leslie St., Toronto, Ontario, M2K 1E1 Canada; fax 416-756-6727, e-mail thuang@nygh.on.ca)

Second-trimester maternal serum screening (MSS) for Down syndrome has been widely used in routine prenatal care in developed countries. The screening combines maternal age-specific risk of Down syndrome with risk estimation obtained by measuring maternal serum markers to assign women an expected risk of having a term Down syndrome pregnancy. Diagnostic tests were offered to women whose risk exceeded the risk cutoff determined by the screening program. The commonly used triple test, which involves the use of maternal age, serum {alpha}-fetoprotein, unconjugated estriol, and human chorionic gonadotropin, was expected to have a Down syndrome detection rate of 60–65% and false-positive rate of 5% (1). Although the expected screening performance has been achieved in many screening programs, the accuracy of individual risk calculated by a relatively complex computation based on a statistical model was not immediately obvious. Good agreement between the expected risk of Down syndrome and observed prevalence has been reported previously in several screening programs (2)(3)(4)(5). We evaluated the accuracy of expected risk of Down syndrome in a large provincial, multiple test center, MSS program in Ontario, Canada.

MSS has been coordinated at the provincial level in Ontario since 1993. Triple maker screening ({alpha}-fetoprotein, unconjugated estriol, and ß-human chorionic gonadotropin) was carried out in seven regional laboratory centers. Information including screen utilization, results, follow-up data, and the pregnancy outcomes of all women screened in the seven centers . . . [Full Text of this Article]


Acknowledgments


References






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American Association for Clinical Chemistry.